Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors
- PMID:24169554
- DOI: 10.1210/en.2013-1658
Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors
Abstract
Amylin is a neuroendocrine hormone involved in glucose regulation. An amylin analog, pramlintide, is used to treat insulin-requiring diabetes. Its anorexigenic actions give it potential as an obesity treatment. There are 3 amylin receptors (AMY1, AMY2, AMY3), comprising the calcitonin receptor and receptor activity-modifying proteins 1, 2, and 3, respectively. The pharmacology of pramlintide at each subtype has not been determined whereas the unrelated peptide β-amyloid 1-42 (Aβ1-42) has recently been proposed to be a specific agonist of the AMY3 receptor. We investigated the actions of Aβ1-42 and pramlintide, compared with human and rat amylin at the calcitonin receptor, AMY1, AMY2, and AMY3 receptors, measuring the cAMP response in human embryonic kidney 293S and Cos 7 cells. Pramlintide activated all receptors with a slight preference for AMY1. No cAMP response was detected with Aβ1-42 at any receptor, suggesting that it may not be a genuine agonist of AMY receptors.
Similar articles
- Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes.Bailey RJ, Walker CS, Ferner AH, Loomes KM, Prijic G, Halim A, Whiting L, Phillips AR, Hay DL.Bailey RJ, et al.Br J Pharmacol. 2012 May;166(1):151-67. doi: 10.1111/j.1476-5381.2011.01717.x.Br J Pharmacol. 2012.PMID:22014233Free PMC article.
- Receptor activity-modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors.Morfis M, Tilakaratne N, Furness SG, Christopoulos G, Werry TD, Christopoulos A, Sexton PM.Morfis M, et al.Endocrinology. 2008 Nov;149(11):5423-31. doi: 10.1210/en.2007-1735. Epub 2008 Jul 3.Endocrinology. 2008.PMID:18599553
- The effects of C-terminal truncation of receptor activity modifying proteins on the induction of amylin receptor phenotype from human CTb receptors.Udawela M, Christopoulos G, Morfis M, Tilakaratne N, Christopoulos A, Sexton PM.Udawela M, et al.Regul Pept. 2008 Jan 10;145(1-3):65-71. doi: 10.1016/j.regpep.2007.08.003. Epub 2007 Aug 16.Regul Pept. 2008.PMID:17884192
- Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development.Bower RL, Hay DL.Bower RL, et al.Br J Pharmacol. 2016 Jun;173(12):1883-98. doi: 10.1111/bph.13496. Epub 2016 May 18.Br J Pharmacol. 2016.PMID:27061187Free PMC article.Review.
- Amylin.Hay DL.Hay DL.Headache. 2017 May;57 Suppl 2:89-96. doi: 10.1111/head.13077.Headache. 2017.PMID:28485843Review.
Cited by
- Distinct Patterns of Internalization of Different Calcitonin Gene-Related Peptide Receptors.Gingell JJ, Rees TA, Hendrikse ER, Siow A, Rennison D, Scotter J, Harris PWR, Brimble MA, Walker CS, Hay DL.Gingell JJ, et al.ACS Pharmacol Transl Sci. 2020 Feb 26;3(2):296-304. doi: 10.1021/acsptsci.9b00089. eCollection 2020 Apr 10.ACS Pharmacol Transl Sci. 2020.PMID:32296769Free PMC article.
- Neuroprotective Effects of Amylin Analogues on Alzheimer's Disease Pathogenesis and Cognition.Grizzanti J, Corrigan R, Casadesus G.Grizzanti J, et al.J Alzheimers Dis. 2018;66(1):11-23. doi: 10.3233/JAD-180433.J Alzheimers Dis. 2018.PMID:30282360Free PMC article.Review.
- Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy.Al-Keilani MS, Alsmadi DH, Darweesh RS, Alzoubi KH.Al-Keilani MS, et al.Clin Pharmacol. 2018 Mar 5;10:23-29. doi: 10.2147/CPAA.S153780. eCollection 2018.Clin Pharmacol. 2018.PMID:29551915Free PMC article.
- The Importance of Understanding Amylin Signaling Mechanisms for Therapeutic Development in the Treatment of Alzheimer's Disease.Servizi S, Corrigan RR, Casadesus G.Servizi S, et al.Curr Pharm Des. 2020;26(12):1345-1355. doi: 10.2174/1381612826666200318151146.Curr Pharm Des. 2020.PMID:32188374Free PMC article.Review.
- Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer's disease.Qiu WQ.Qiu WQ.Neuroscience. 2017 Jul 25;356:44-51. doi: 10.1016/j.neuroscience.2017.05.024. Epub 2017 May 19.Neuroscience. 2017.PMID:28528968Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous